TISSUETECH

tissuetech-logo

TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics. Tissuetech was founded in 2001 and is headquartered in Miami, Florida.

#People #Financial #Website #More

TISSUETECH

Industry:
Biotechnology Health Care Medical Medical Device Pharmaceutical

Founded:
2001-01-01

Address:
Miami, Florida, United States

Country:
United States

Website Url:
http://www.tissuetech.com

Total Employee:
251+

Status:
Active

Contact:
786-817-6690

Email Addresses:
[email protected]

Total Funding:
110.04 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail ReCAPTCHA Microsoft Azure DNS Google Google Cloud Gravity Forms Network Solutions DNS Mimecast



Current Advisors List

carter-mcnabb_image

Carter McNabb Board Member @ Tissuetech
Board_member
2013-08-22

matt-rice_image

Matt Rice Board Member @ Tissuetech
Board_member
2013-08-22

Current Employees Featured

amy-h-tseng_image

Amy H. Tseng
Amy H. Tseng Founder and Board Member @ Tissuetech
Founder and Board Member
2022-01-01

michael-cornelius_image

Michael Cornelius
Michael Cornelius Chief Financial Officer @ Tissuetech
Chief Financial Officer

scheffer-cg-tseng_image

Scheffer C.G. Tseng
Scheffer C.G. Tseng Chief Technology Officer @ Tissuetech
Chief Technology Officer
2002-01-01

devin-buckley_image

Devin Buckley
Devin Buckley Corporate Legal Counsel and Chief Compliance Officer @ Tissuetech
Corporate Legal Counsel and Chief Compliance Officer

tom-williamson_image

Tom Williamson
Tom Williamson Chief Commercial Officer @ Tissuetech
Chief Commercial Officer

not_available_image

Yiling Hsu
Yiling Hsu CIO @ Tissuetech
CIO

Founder


amy-h-tseng_image

Amy H. Tseng

scheffer-cg-tseng_image

Scheffer C.G. Tseng

Investors List

essex-woodlands-health-ventures_image

Essex Woodlands Healthcare Partners

Essex Woodlands Healthcare Partners investment in Series C - Tissuetech

ballast-point-ventures_image

Ballast Point Ventures

Ballast Point Ventures investment in Series C - Tissuetech

river-cities-capital_image

RC Capital

RC Capital investment in Series B - Tissuetech

ballast-point-ventures_image

Ballast Point Ventures

Ballast Point Ventures investment in Series B - Tissuetech

river-cities-capital_image

RC Capital

RC Capital investment in Series A - Tissuetech

ballast-point-ventures_image

Ballast Point Ventures

Ballast Point Ventures investment in Series A - Tissuetech

Official Site Inspections

http://www.tissuetech.com

  • Host name: 27.203.184.35.bc.googleusercontent.com
  • IP address: 35.184.203.27
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Tissuetech"

BioTissue - Crunchbase Company Profile & Funding

BioTissue is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and …See details»

TissueTech Company Profile - Craft

TissueTech has 5 employees across 2 locations and $110.04 m in total funding,. See insights on TissueTech including office locations, competitors, revenue, financials, executives, …See details»

TISSUETECH AT A GLANCE

%PDF-1.6 %âãÏÓ 50 0 obj > endobj 79 0 obj >/Filter/FlateDecode/ID[]/Index[50 43]/Info 49 0 R/Length 132/Prev 102606/Root 51 0 R/Size 93/Type/XRef/W[1 3 1]>>stream ...See details»

Working At TissueTech: Company Overview and Culture - Zippia

Mar 14, 2024 Organization Type. Private. CEO. Ted Davis. Social Media. TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical …See details»

TissueTech Announces Rebranding, Adopts BioTissue Name …

Mar 8, 2022 TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and …See details»

TissueTech Announces Rebranding, Adopts BioTissue Name …

Feb 9, 2022 By adopting the BioTissue name across the entire organization, the company will also reflect that innovative heritage and promise in its surgical business, which was previously …See details»

TissueTech - VentureRadar

"Bio-Tissue, Inc. is the leader in human birth tissue products for use in the treatment of patients with ocular surface disease and disorders. Bio-Tissue is the only provider of cryopreserved …See details»

Tissuetech | CipherBio

Explore Tissuetech's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»

TissueTech Announces Rebranding, Adopts BioTissue Name …

Feb 9, 2022 TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and …See details»

TissueTech Announces Rebranding, Adopts BioTissue Name …

Feb 9, 2022 MIAMI--(BUSINESS WIRE)-- TissueTech, Inc.a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, …See details»

TissueTech CEO And Leadership: Executives and Demographics

Nov 18, 2022 Here are further demographic highlights of the leadership team: The TissueTech executive team is 29% female and 71% male.; 59% of the management team is White.; 6% of …See details»

TissueTech CEO and Key Executive Team | Craft.co

TissueTech's President, CEO is Amy Tseng. Other executives include Scheffer C.G. Tseng, Chief Technology Officer; Devin Buckley, Chief Compliance Officer, Corporate Legal Counsel and 2 …See details»

TissueTech Announces Rebranding, Adopts BioTissue Name …

Feb 15, 2022 TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and …See details»

BioTissue - Funding, Financials, Valuation & Investors - Crunchbase

BioTissue has a post-money valuation in the range of $100M to $500M as of Jun 27, 2019, according to PrivCo.Sign up for a free trial to view exact valuation and search companies with …See details»

Ted Davis to Succeed Amy Tseng as President and CEO of …

Jan 27, 2022 “I am pleased to transition leadership of the organization to Ted, as I know he will bring new energy, experience and ideas to this next phase of growth for TissueTech.” About …See details»

TissueTech Management Team - CB Insights

Pegasus Biologics is a contract research organization specializing in biopharmaceuticals and DNA vaccines within the biotechnology sector. The company offers services such as analytical …See details»

How TissueTech Managed Growth Virtual Trials And Survived …

Aug 11, 2020 Those patients oftentimes face amputation and a subsequent mortality rate that can be as high as 50 percent in five years. Still, the pandemic forced TissueTech to delay the …See details»

TISSUETECH: Receives Regenerative Medicine Advanced Therapy …

Apr 17, 2020 TissueTech issued the following announcement on April 16. TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue …See details»

TissueTech Receives Regenerative Medicine Advanced Therapy …

MIAMI, April 16, 2020 /PRNewswire/ -- TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products, announced today that the U.S. …See details»

linkstock.net © 2022. All rights reserved